Shares of Eris Lifesciences Ltd experienced robust buying interest, closing 11.04 percent higher at Rs 1,484.95 on Monday. This strong performance followed the pharmaceutical firm's announcement of its March 2026 quarter (Q4 FY26) results, revealing a remarkable 200.10 percent year-on-year (YoY) increase in consolidated net profit.
The company reported a consolidated net profit of Rs 281.61 crore for Q4 FY26, a substantial rise from Rs 93.84 crore recorded in the corresponding quarter of the previous year. This sharp boost in profitability was primarily attributed to a deferred tax gain of Rs 132.18 crore during the quarter, significantly higher than the Rs 4.87 crore deferred tax gain in the year-ago period.
Revenue Growth and Operational Performance
Eris Lifesciences also saw its revenue climb 7 percent to Rs 757 crore in Q4 FY26, up from Rs 705 crore in the same period last year. Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) increased by 8 percent YoY, reaching Rs 274 crore compared to Rs 252 crore previously. The company's EBITDA margin also showed a marginal improvement, rising to 36.2 percent from 35.8 percent a year ago.
Interim Dividend Declaration
Alongside the impressive financial results, the company's Board of Directors approved an interim dividend payment of Rs 7.21 per share for the Financial Year 2026-2027. This translates to a generous payout of 721 percent on each fully paid-up equity share of Re 1/- each.
Dividend Record and Payment Dates
Eris Lifesciences has set May 29, 2026, as the record date for determining the eligibility of shareholders for this interim dividend. Eligible shareholders can expect to receive their dividend payments on or before June 19, 2026.